Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) have been given an average recommendation of “Hold” by the six brokerages that are covering the firm, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $15.50.

TNDM has been the subject of a number of research analyst reports. Zacks Investment Research raised Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research report on Wednesday, November 1st. Piper Jaffray Companies reaffirmed a “hold” rating and set a $15.00 price target on shares of Tandem Diabetes Care in a research report on Friday, October 6th. Finally, Wedbush reaffirmed an “outperform” rating and set a $17.00 price target (down from $50.00) on shares of Tandem Diabetes Care in a research report on Tuesday, October 10th.

In other news, CEO Kim D. Blickenstaff bought 285,700 shares of the firm’s stock in a transaction on Friday, October 13th. The stock was acquired at an average cost of $3.50 per share, with a total value of $999,950.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 20.90% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in TNDM. Bank of America Corp DE increased its position in Tandem Diabetes Care by 88.6% in the first quarter. Bank of America Corp DE now owns 861,026 shares of the medical device company’s stock worth $1,032,000 after buying an additional 404,452 shares during the last quarter. Russell Investments Group Ltd. increased its position in Tandem Diabetes Care by 93.3% in the second quarter. Russell Investments Group Ltd. now owns 581,245 shares of the medical device company’s stock worth $465,000 after buying an additional 280,551 shares during the last quarter. Keybank National Association OH increased its position in Tandem Diabetes Care by 32.7% in the second quarter. Keybank National Association OH now owns 293,206 shares of the medical device company’s stock worth $235,000 after buying an additional 72,177 shares during the last quarter. Vanguard Group Inc. increased its position in Tandem Diabetes Care by 2.7% in the second quarter. Vanguard Group Inc. now owns 1,233,607 shares of the medical device company’s stock worth $987,000 after buying an additional 32,991 shares during the last quarter. Finally, Wedbush Securities Inc. increased its position in Tandem Diabetes Care by 88.6% in the third quarter. Wedbush Securities Inc. now owns 188,877 shares of the medical device company’s stock worth $138,000 after buying an additional 88,709 shares during the last quarter.

Shares of Tandem Diabetes Care (NASDAQ:TNDM) opened at $2.93 on Friday. The company has a debt-to-equity ratio of -2.70, a quick ratio of 0.88 and a current ratio of 1.90. Tandem Diabetes Care has a 52-week low of $2.15 and a 52-week high of $32.50.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings results on Thursday, October 26th. The medical device company reported ($3.09) EPS for the quarter, beating the Zacks’ consensus estimate of ($3.74) by $0.65. The company had revenue of $27.00 million during the quarter, compared to the consensus estimate of $25.92 million. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 79.45%. Tandem Diabetes Care’s revenue was up 119.7% on a year-over-year basis. During the same period last year, the business posted ($0.97) earnings per share. research analysts predict that Tandem Diabetes Care will post -15.18 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was posted by Daily Political and is owned by of Daily Political. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of international trademark and copyright law. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/11/19/tandem-diabetes-care-inc-tndm-receives-consensus-recommendation-of-hold-from-brokerages.html.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).

Analyst Recommendations for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with MarketBeat.com's FREE daily email newsletter.